Orchard Therapeutics (ORTX) to Release Quarterly Earnings on Thursday

Share on StockTwits

Orchard Therapeutics (NASDAQ:ORTX) will be announcing its earnings results before the market opens on Thursday, March 21st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Orchard Therapeutics stock opened at $14.90 on Friday. Orchard Therapeutics has a twelve month low of $8.65 and a twelve month high of $19.24.

Several analysts have commented on ORTX shares. Wedbush started coverage on shares of Orchard Therapeutics in a research report on Sunday, December 2nd. They issued an “outperform” rating and a $16.80 target price for the company. JPMorgan Chase & Co. started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set an “overweight” rating and a $25.00 price objective for the company. Cowen started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set an “outperform” rating and a $27.00 price objective for the company. Goldman Sachs Group started coverage on shares of Orchard Therapeutics in a report on Monday, November 26th. They set a “neutral” rating and a $18.00 price objective for the company. Finally, ValuEngine downgraded shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $22.45.

ILLEGAL ACTIVITY NOTICE: “Orchard Therapeutics (ORTX) to Release Quarterly Earnings on Thursday” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4222892/orchard-therapeutics-ortx-to-release-quarterly-earnings-on-thursday.html.

Orchard Therapeutics Company Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: Why are percentage decliners important?

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Numis Securities Cuts Just Group  Price Target to GBX 160
Numis Securities Cuts Just Group Price Target to GBX 160
Marshalls  Downgraded by Berenberg Bank to Hold
Marshalls Downgraded by Berenberg Bank to Hold
SEGRO  Stock Rating Reaffirmed by Deutsche Bank
SEGRO Stock Rating Reaffirmed by Deutsche Bank
Team17 Group  Price Target Increased to GBX 255 by Analysts at Liberum Capital
Team17 Group Price Target Increased to GBX 255 by Analysts at Liberum Capital
SYSCO  versus Innovative Food  Head to Head Contrast
SYSCO versus Innovative Food Head to Head Contrast
Critical Comparison: Allegheny Technologies  vs. Haynes International
Critical Comparison: Allegheny Technologies vs. Haynes International


Leave a Reply

© 2006-2019 Ticker Report